The future of precision medicine part 6: reimbursement
In future, the more efficient targeting of treatments to specific patient populations that will actually benefit from them, could offset the price of more expensive but well targeted and effective treatments that will be suitable for increasingly smaller patient populations. Daniel Lim and Anna Jackson of Kirkland & Ellis explain.
The future of precision medicine part 5: keeping pace with regulation
One of the perennial inherent challenges for legislators and regulators is crafting laws and regulatory frameworks that are firm enough to deal with the issues of the present, but flexible enough to cater for the challenges of the future, as Daniel Lim and Anna Jackson of Kirkland & Ellis explain.
Conference preview: Women Leaders in Life Sciences Law
The next event in ACI’s Women Leaders in Law series, on July 25 & 26 in Boston, brings together in-house and private practice professionals from the pharmaceutical, biotechnology, and medical device industries.
C5’s 18th International forum on Pharmaceutical Patent Term Extensions
European legislators and patent offices, and in-house pharma decision-makers will tackle current patent term extension challenges on June 25 & 26 at the Maritim Hotel München, Munich.
Precision medicine: The personal touch
Precision medicine is an evolving field, which takes individual variability in genes, environment, and lifestyle into account when tackling disease treatment and prevention. LSIPR reports.
Shire Pharmaceuticals: A culture of excellence
LSIPR provides a look behind the scenes of Shire Pharmaceuticals, the Irish company valued at £46 billion by its acquirer Takeda.
Women in STEM: Bridging the gender gap
A plethora of studies have indicated that diversity drives innovation and economic performance, so why are the STEM fields, where innovation is the life-blood, so behind on gender diversity? WIPR investigates the reasons behind the failure to attract and retain women, and what needs to be done.
Marketing authorisation: Splitting the bill
An increasing number of pharmaceutical companies are turning to joint representation—where they pool their funds and hire one firm to represent them all—for ANDA litigation. Mark Remus, shareholder at Brinks Gilson & Lione, outlines the pros and cons of this new direction.
SPCs: extending protection lifespan
Two references to the Court of Justice of the European Union should help clarify the position on what exactly is eligible for a supplementary protection certificate, as Michael Pears and Joel Beevers of Potter Clarkson explain.
The heart of the 3D printing matter
3D-printed organs and tissues are now a reality, but questions remain over their patentability, says Gabriel Di Blasi of Di Blasi, Parente & Associados.
